In conclusion, our integrative analysis targeting the TME of HER2 + IBC and nIBC patients revealed a stronger immunosuppressive molecular signature in HER2 + IBC patients, suggesting that cellular interaction pathways mediated by the PTN-TNF molecular axis, which are specific to HER2 + IBC tumours, are potentially important therapeutic targets. Here, ERBB2 is linked to inflammatory breast carcinoma.